Timing clarification: Cencora is scheduled to report before the market opens on Wednesday, August 5, 2026, with its earnings call at 8:30 a.m. ET. Given today’s date is August 5, this is today’s event—not tomorrow’s.
Cencora enters fiscal 3Q26 with a clear debate: the company cut its revenue-growth outlook last quarter because of slower GLP-1 growth, manufacturer price reductions, and faster biosimilar conversion at a large mail-order customer—but it simultaneously raised adjusted EPS guidance. The report must therefore validate that mix changes are largely revenue issues rather than a structural hit to dollar profit or operating-income growth.
The central test is whether Cencora can deliver the high-single-digit adjusted EPS growth management specifically guided for in fiscal Q3, while reaffirming the framework for a substantially stronger fiscal Q4.
At fiscal 2Q26 results, Cencora raised FY26 adjusted diluted EPS guidance to $17.65–$17.90, from $17.45–$17.75. It retained expectations for:
| FY26 metric | Current guidance |
|---|---|
| Consolidated revenue growth | 4%–6% |
| U.S. Healthcare Solutions revenue growth | 4%–6% |
| International Healthcare Solutions revenue growth | 8%–10% reported |
| Consolidated adjusted operating-income growth | 12%–14% |
| U.S. Healthcare Solutions operating-income growth | 14%–16% |
| International Healthcare Solutions operating-income growth | 5%–8% |
| Adjusted EPS | $17.65–$17.90 |
| Net interest expense | ~$485 million |
| Adjusted tax rate | ~20% |
| Adjusted free cash flow | ~$3.0 billion |
For fiscal Q3 specifically, management said to expect high-single-digit adjusted EPS growth and net interest expense roughly in line with Q2’s $140 million. Against fiscal 3Q25 adjusted EPS of $4.00, that implies a directional Q3 EPS bogey around $4.32–$4.40.
The arithmetic also makes the back half important. Cencora earned $8.83 in adjusted EPS through the first six months. A roughly $4.3–$4.4 Q3 would leave a sizeable $4.4–$4.8 of implied Q4 adjusted EPS needed to reach the full-year guide. That makes the credibility of management’s Q4 acceleration commentary a key share-price driver.
In fiscal Q2, U.S. Healthcare Solutions revenue grew only 2.9%, while segment operating income grew 5.6%. Revenue was held back by:
Management’s position is that the mail-order conversion is mainly a low-margin revenue headwind, not a material profit headwind, and that manufacturer price changes can be commercially managed to preserve dollar economics.
Investors should look for proof in the following metrics:
A clean outcome would be stable or improving profit performance even if revenue remains below historical growth rates.
Cencora completed its acquisition of OneOncology in February 2026. The transaction lifted gross-profit and operating-expense dollars in Q2, while management indicated that accretion should ramp through the year.
The company has also emphasized collaboration between OneOncology and Retina Consultants of America (RCA), particularly in clinical trials, administrative functions, physician recruitment and retention, and sharing operating practices. These assets increase Cencora’s exposure to physician-administered specialty therapies and Part B economics—an area management believes benefits from biosimilar adoption, in contrast to the mail-order/Part D channel.
Key questions:
International Healthcare Solutions delivered fiscal Q2 revenue growth of 13.0% reported and 7.2% constant currency, with operating income up 13.7% reported. The result benefited from European distribution growth and a continued rebound at global specialty logistics/World Courier.
This is important because the prior-year Q3 comparison was weak: fiscal 3Q25 International operating income declined 12.9%, largely due to global specialty logistics and consulting-service pressure. Cencora’s Q2 call suggested logistics had now produced two consecutive quarters of operating-income growth and had won contracts in cell and gene therapy and laboratory logistics.
A sustained logistics recovery and stable European distribution margins would strengthen confidence in the 5%–8% FY26 International operating-income target.
| Metric | Fiscal 3Q25 actual | Fiscal 3Q26 setup |
|---|---|---|
| Revenue | $80.7B | Revenue growth should be judged against a reduced FY26 4%–6% framework |
| Adjusted operating income | $1.06B | Focus on U.S. margin progression, OneOncology ramp, and International recovery |
| Adjusted EPS | $4.00 | Management indicated high-single-digit growth |
| Net interest expense | $81.8M | Expected at roughly $140M, reflecting OneOncology financing |
| Adjusted tax rate | 20.7% | FY26 target is approximately 20% |
The comparison is more demanding on interest expense and less demanding in International, where the company faces easier comparisons following last year’s logistics weakness.
COR closed at $306.32 on August 4. The stock fell roughly 17% following the May 6 Q2 report, when the company reduced revenue guidance despite lifting EPS guidance, but subsequently recovered more than 21% from its May 6 close. It remains modestly below its late-July high.
That price action suggests investors have already focused on the distinction between revenue growth and earnings quality. Accordingly, a simple EPS beat may not be enough: the stock reaction is likely to hinge on whether management can reinforce the message that lower-margin revenue pressure is manageable while operating income, cash flow, and the MSO-led specialty strategy remain intact.
Cencora’s fiscal 3Q26 report is principally an execution and earnings-quality test. The most constructive outcome would be high-single-digit EPS growth, stable U.S. profit performance despite muted revenue, continuing International/logistics recovery, and clear reaffirmation that OneOncology accretion plus easier comparisons support the expected Q4 step-up.
Conversely, another reduction to revenue expectations may be tolerated if operating-income and EPS guidance remain protected. What would matter more negatively is any indication that GLP-1, price, biosimilar, or customer-channel dynamics are eroding dollar profit, challenging the company’s 12%–14% FY26 adjusted operating-income growth target.